These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2514478)

  • 1. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back.
    Patrono C
    Trends Pharmacol Sci; 1989 Nov; 10(11):453-8. PubMed ID: 2514478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting.
    Mattiello T; Guerriero R; Lotti LV; Trifirò E; Felli MP; Barbarulo A; Pucci B; Gazzaniga P; Gaudio C; Frati L; Pulcinelli FM
    J Am Coll Cardiol; 2011 Aug; 58(7):752-61. PubMed ID: 21816313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose enteric-coated aspirin: a practical approach to continuous-release low-dose aspirin and presystemic acetylation of human platelet cyclooxygenase.
    Jakubowski JA; Stampfer MJ; Vaillancourt R; Faigel D; Deykin D
    J Lab Clin Med; 1986 Dec; 108(6):616-21. PubMed ID: 3097223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery.
    Zimmermann N; Wenk A; Kim U; Kienzle P; Weber AA; Gams E; Schrör K; Hohlfeld T
    Circulation; 2003 Aug; 108(5):542-7. PubMed ID: 12874188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase.
    Pedersen AK; FitzGerald GA
    N Engl J Med; 1984 Nov; 311(19):1206-11. PubMed ID: 6436696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin resistance and platelet turnover: a 25-year old issue.
    Di Minno G
    Nutr Metab Cardiovasc Dis; 2011 Aug; 21(8):542-5. PubMed ID: 21745731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mechanism of changes in the platelet functional activity caused by low energy laser irradiation].
    Spasov AA; Nedogoda VV; Konan K
    Biull Eksp Biol Med; 1998 Jul; 126(7):45-8. PubMed ID: 9777195
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of platelet prostaglandin synthetase by oral aspirin.
    Burch JW; Stanford N; Majerus PW
    J Clin Invest; 1978 Feb; 61(2):314-9. PubMed ID: 413839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
    Capone ML; Tacconelli S; Sciulli MG; Grana M; Ricciotti E; Minuz P; Di Gregorio P; Merciaro G; Patrono C; Patrignani P
    Circulation; 2004 Mar; 109(12):1468-71. PubMed ID: 15037526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
    Clarke RJ; Mayo G; Price P; FitzGerald GA
    N Engl J Med; 1991 Oct; 325(16):1137-41. PubMed ID: 1891022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: aspirin resistance--fact or fashion?
    Patrono C; Rocca B
    Nat Clin Pract Cardiovasc Med; 2007 Jan; 4(1):42-50. PubMed ID: 17180149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin, platelets and prevention of vascular disease.
    de Gaetano G; Cerletti C
    J Lipid Mediat; 1989; 1(5):289-96. PubMed ID: 2519899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.
    Cerletti C; Gambino MC; Garattini S; de Gaetano G
    J Clin Invest; 1986 Jul; 78(1):323-6. PubMed ID: 3088044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin.
    Evangelista V; Manarini S; Di Santo A; Capone ML; Ricciotti E; Di Francesco L; Tacconelli S; Sacchetti A; D'Angelo S; Scilimati A; Sciulli MG; Patrignani P
    Circ Res; 2006 Mar; 98(5):593-5. PubMed ID: 16484611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation.
    Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C
    Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin as an antithrombotic drug: from the aggregometer to clinical trials.
    de Gaetano G
    Verh K Acad Geneeskd Belg; 1990; 52(6):459-71; discussion 471-3. PubMed ID: 2150736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2.
    FitzGerald GA; Lupinetti M; Charman SA; Charman WN
    J Pharmacol Exp Ther; 1991 Dec; 259(3):1043-9. PubMed ID: 1762060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.